Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide as Neoadjuvant Therapy for Surgical Treatment of Type 2 Diabetes
NCT04624672Phase 4Terminated
- Sponsor
- Geisinger
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Geisinger. Started Aug 2021; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04624672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624672.